Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

avera mckennan hospital - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 1 mg

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

actavis pharma, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 0.5 mg

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 1 mg

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

cardinal health - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 1 mg

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

avera mckennan hospital - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 0.5 mg

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol, quantity: 5.69 mg - drug delivery system, transdermal - excipient ingredients: ethyl oleate; isopropyl myristate; glyceryl laurate; acrylates/acrylamide copolymer - other conditions: do not remove from primary pack except for immediate use. for short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. oestradiol prevents the accelerated loss of bone density due to oestrogen deficiency and may be used for the prevention of post-menopausal bone mineral density loss. in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.,for short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. for the prevention of post menopausal bone mineral density loss. when prescribed solely for the prevention of post menopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who, are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. lifestyle modifications and the risk benefit profile of climara should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing (see precautions and dosage and administration sections). in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol, quantity: 1.97 mg - drug delivery system, transdermal - excipient ingredients: glyceryl laurate; ethyl oleate; isopropyl myristate; acrylates/acrylamide copolymer - other condition: do not remove from primary pack except for immediate use. for short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. oestradiol prevents the accelerated loss of bone density due to oestrogen deficiency and may be used for the prevention of post-menopausal bone mineral density loss. in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.,for short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. for the prevention of post menopausal bone mineral density loss. when prescribed solely for the prevention of post menopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who, are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. lifestyle modifications and the risk benefit profile of climara should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing (see precautions and dosage and administration sections). in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol, quantity: 7.6 mg - drug delivery system, transdermal - excipient ingredients: isopropyl myristate; ethyl oleate; glyceryl laurate; acrylates/acrylamide copolymer - other conditions: do not remove from primary pack except for immediate use. indications: for short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. oestradiol prevents the accelerated loss of bone density due to oestrogen deficiency and may be used for the prevention of post menopausal bone mineral density loss. in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.,for short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. for the prevention of post menopausal bone mineral density loss. when prescribed solely for the prevention of post menopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who, are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. lifestyle modifications and the risk benefit profile of climara should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing (see precautions and dosage and administration sections). in women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

bryant ranch prepack - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol tablets are indicated in the: 1.    treatment of moderate to severe vasomotor symptoms associated with the menopause.  2.    treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribed solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.  3.    treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4.    treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. 5.    treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). 6.    prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate (see clinical pharmacology, clinical studies .) the mainstays for decreasing the

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol tablets are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. - treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). - prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (see clinical pharmacology , clinical studies. ) - the m